| Dr John C Kulze Iii, MD | |
|
2270 Ashley Crossing Dr, Ste 100, Charleston, SC 29414 | |
| (843) 556-2357 | |
| (843) 556-0350 |
| Full Name | Dr John C Kulze Iii |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 35 Years |
| Location | 2270 Ashley Crossing Dr, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497733794 | NPI | - | NPPES |
| PA6314 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 13052 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eye Center Of Charleston | 9032210083 | 4 |
News Archive
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.
A combined treatment with rapamycin and Gleevec might reverse the effects of portal hypertension in patients with chronic liver disease, according to the results of a new study on rats.
Though rats, fish oil and beetroot juice read like ingredients in a witch's brew, to a Kansas State University research team, information from this combination could lead to health breakthroughs for aging populations and people suffering from heart failure and diabetes.
LifeCycle Pharma A/S (OMX: LCP) announced today that the Board of Directors of LCP and Jim New have agreed to terminate the contract with Jim New. Hence, Jim New will with immediate effect step down as the President and CEO of LCP. The termination is related to different views on how an international company based in Scandinavia shall be managed.
› Verified 7 days ago
| Entity Name | Eye Center Of Charleston |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811905839 PECOS PAC ID: 9032210083 Enrollment ID: O20070720000725 |
News Archive
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.
A combined treatment with rapamycin and Gleevec might reverse the effects of portal hypertension in patients with chronic liver disease, according to the results of a new study on rats.
Though rats, fish oil and beetroot juice read like ingredients in a witch's brew, to a Kansas State University research team, information from this combination could lead to health breakthroughs for aging populations and people suffering from heart failure and diabetes.
LifeCycle Pharma A/S (OMX: LCP) announced today that the Board of Directors of LCP and Jim New have agreed to terminate the contract with Jim New. Hence, Jim New will with immediate effect step down as the President and CEO of LCP. The termination is related to different views on how an international company based in Scandinavia shall be managed.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John C Kulze Iii, MD 2270 Ashley Crossing Dr, Ste 100, Charleston, SC 29414 Ph: (843) 556-2357 | Dr John C Kulze Iii, MD 2270 Ashley Crossing Dr, Ste 100, Charleston, SC 29414 Ph: (843) 556-2357 |
News Archive
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.
A combined treatment with rapamycin and Gleevec might reverse the effects of portal hypertension in patients with chronic liver disease, according to the results of a new study on rats.
Though rats, fish oil and beetroot juice read like ingredients in a witch's brew, to a Kansas State University research team, information from this combination could lead to health breakthroughs for aging populations and people suffering from heart failure and diabetes.
LifeCycle Pharma A/S (OMX: LCP) announced today that the Board of Directors of LCP and Jim New have agreed to terminate the contract with Jim New. Hence, Jim New will with immediate effect step down as the President and CEO of LCP. The termination is related to different views on how an international company based in Scandinavia shall be managed.
› Verified 7 days ago
Kenneth A Sharpe, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3531 Mary Ader Ave, Charleston, SC 29414 Phone: 843-352-0674 | |
Dr. Andrew Steven Eiseman, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. Scott Alan Davis, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. Hao Tang, M.D., PH.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 167 Ashley Ave # Msc676, Charleston, SC 29425 Phone: 843-792-2020 Fax: 843-792-1166 | |
M Edward Wilson, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. Edward William Trudo Jr., M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 109 Bee St, Charleston, SC 29401 Phone: 843-577-5011 | |
John Weaver, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 |